Latest Drug Development Stories
CLEVELAND, June 19, 2013 /PRNewswire/ -- DATATRAK International, Inc. (OTCQX: DTRK), a leader in developing cloud-based, unified eClinical® technologies and delivering related services for the clinical trials industry, today announced their partnership with SAS to provide SAS® Drug Development as an extension of the DATATRAK ONE(TM) solution. (Logo: http://photos.prnewswire.com/prnh/20130107/CL38347LOGO) "As the innovator in cloud-based eClinical solutions, DATATRAK brings the...
Researchers believe the 'undruggable' may be druggable Harvard Stem Cell Institute (HSCI) researchers have identified in the most aggressive forms of cancer a gene known to regulate embryonic stem cell self-renewal, beginning a creative search for a drug that can block its activity. The gene, SALL4, gives stem cells their ability to continue dividing as stem cells rather than becoming mature cells. Typically, cells only express SALL4 during embryonic development, but the gene is...
THE WOODLANDS, Texas, June 18, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that John Northcott has joined the company as its vice president of marketing, commercial strategy, and operations. Mr. Northcott brings extensive commercial experience to Lexicon, including both pre-launch planning and on-market commercialization across a variety of therapeutic...
New open-access website also documents over 250,000 predicted protein kinase drug interactions using proprietary algorithms VANCOUVER, June 12, 2013 /PRNewswire/ - Kinexus Bioinformatics Corporation, a world-leader in the study of molecular intelligence systems, announced the launch of its DrugKiNET KnowledgeBase (www.drugkinet.ca) for the identification and development of drug candidates that potently and selectively inhibit human protein kinases. This open-access website...
Annual Meeting to Address Urgent Issues Impacting Stakeholders Horsham, Pa. (PRWEB) June 05, 2013 Patient engagement, financial backing and personalized medicine—three of the most pressing issues in drug development and regulatory affairs—will be discussed at length at the DIA 2013 49th Annual Meeting, June 23-27 in Boston. Today’s thought leaders, decision-makers and patient advocates will have a unique opportunity to collaborate and share knowledge with today’s top minds in...
NKTR-214 Demonstrates Improved Efficacy and Better Tolerability in Aggressive and Resistant Preclinical Melanoma Model SAN FRANCISCO, June 3, 2013 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced positive preclinical data for NKTR-214, an investigational cancer immunotherapy which targets the IL-2 receptor complex and is being developed as a potential treatment for multiple cancers. The results were presented today at the 2013 ASCO Annual Meeting in Chicago. NKTR-214...
COLORADO SPRINGS, Colo., May 29, 2013 /PRNewswire/ -- Cannabis Science, Inc. (NASD OTC: CBIS), announced today the appointment of clinical development expert, Dr. Dorothy Bray, Ph.D., as Chief Executive Officer and Director. Dr. Bray served as Head of Scientific Business Development of The Medical Research Council Clinical Trials Unit in the UK. She also held various positions of responsibility at GlaxoSmithKline as Global Director of HIV Research and Senior Clinical Program Head of...
BALTIMORE, May 29, 2013 /PRNewswire/ -- UPM Pharmaceuticals, a Baltimore, Maryland-based drug development and contract manufacturer, announced today that they will be acquiring the 500,000 square-foot commercial manufacturing facility that Pfizer Inc. (PFE) currently operates in Bristol, TN. The acquisition of the Pfizer facility will provide UPM with large scale commercial capabilities for manufacturing and packaging of solid oral dosage tablets and capsules, as well as...
The company will host a complimentary webinar on Tuesday, June 11, 2013 at 2:15 p.m. British Summer Time (9:15 a.m. Eastern Standard Time). (PRWEB) May 28, 2013 Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, will host a complimentary webinar on “Accelerating the Drug Development Trajectory by Improving Solubility of New Compounds” on Tuesday, June 11, 2013 at 2:15 p.m. British Summer Time (9:15 a.m. Eastern...
NORTH BRUNSWICK, N.J., May 21, 2013 /PRNewswire/ -- Hurel Corporation ("Hurel"), a world-leading provider of advanced artificial tissue constructs and microfluidic cell-based assay platforms, today announced the appointment of James S. MacDonald, PhD, DABT to the Company's Board of Directors. Dr. MacDonald is the former Executive Vice President of Preclinical Development of the Schering-Plough Research Institute ("SPRI"), which was the pharmaceutical development arm of Schering...
